Integrated One-stop Drug Discovery Platform Accelerating Project with High Efficiency
HitGen has an industry-leading pipeline of targets addressing unmet needs in ophthalmology, such as glaucoma, ocular hypertension and wet age-related macular degeneration. By leveraging our DEL screening technology platform, our scientists has developed innovative candidates in preclinical stage for treating glaucoma disease.
Services for ophthalmology diseases drug discovery and development
Target Validation
Biochemical assays development
DEL Screening
Hit identification and generation
Hit-to-Lead
Lead optimization
Fragment-based drug discovery and structure-based drug discovery
Co-crystal structure generation and resolution
in vitro efficacy and ADME evaluation
in vivo pharmacology
Drug metabolism and pharmacokinetics (DMPK)
Safety
IND submission
HitGen Inc.
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Vernalis (R&D) Limited (UK Subsidiary)
Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom
Tel : +44(0)1223-895555
川公网安备 51012202000492号
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information
